VIDEO: Pangenotypic regimen leads to high SVR in all HCV genotypes

[HFIAdmin]

Positive news for patients of any HCV genotypes! After treatment with AbbVie’s new pangenotypic regimen of glecaprevir/pibrentasvir, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy.

bit.ly/2ggJHjr